Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

BenzingaOct 17 14:32 ET

This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

BenzingaOct 17 09:05 ET

Express News | Alumis Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $30

ReutersOct 17 06:05 ET

Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock'

BenzingaOct 9 08:36 ET

Buy Rating Affirmed for Alumis Inc. as ESK-001 Shows Promise in Psoriasis Treatment Trials

TipRanksSep 29 20:45 ET · Ratings

Alumis Shares Are Trading Lower. The Company Presented the 28-week Open Label Extension Period Data From Its Phase 2 STRIDE Trial of ESK-001.

BenzingaSep 27 13:17 ET